Genetic Polymorphisms and Adverse Events on Unbound Imatinib and Its Active Metabolite Concentration in Patients With Gastrointestinal Stromal Tumors

Genetic variations of the xenoreceptors NR1I2 and NR1I3 and their effect on drug disposition and response variability

(2018) Litaty Céphanoée Mbatchi et al.   PHARMACOGENOMICS

Simple LC-MS/MS Methods Using Core-Shell ODS Microparticulate for the Quantitation of Total and Free Daptomycin in Human Plasma

(2018) Yukari Miyadera et al.   THERAPEUTIC DRUG MONITORING

Genetic Polymorphisms Contribute to the Individual Variations of Imatinib Mesylate Plasma Levels and Adverse Reactions in Chinese GIST Patients

(2017) Jing Liu et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Analysis of common polymorphisms within NR1I2 and NR1I3 genes and tacrolimus dose-adjusted concentration in stable kidney transplant recipients

(2017) Mateusz Kurzawski et al.   Pharmacogenetics and Genomics

Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial

(2016) Jeffrey H Lipton et al.   LANCET ONCOLOGY

A study to explore the correlation of ABCB1, ABCG2, OCT1 genetic polymorphisms and trough level concentration with imatinib mesylate-induced thrombocytopenia in chronic myeloid leukemia patients

(2015) Jose Francis et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

A validated LC–MS/MS method of total and unbound lenvatinib quantification in human serum for protein binding studies by equilibrium dialysis

(2015) Yuji Mano et al.   JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS

Association of ABCG2 polymorphism with clinical efficacy of imatinib in patients with gastrointestinal stromal tumor

(2014) Dong-Hoe Koo et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Cellular Uptake of Imatinib into Leukemic Cells Is Independent of Human Organic Cation Transporter 1 (OCT1)

(2013) A. T. Nies et al.   CLINICAL CANCER RESEARCH

Single-nucleotide polymorphisms of ABCG2 increase the efficacy of tyrosine kinase inhibitors in the K562 chronic myeloid leukemia cell line

(2013) Karin Skoglund et al.   Pharmacogenetics and Genomics

Should therapeutic drug monitoring of the unbound fraction of imatinib and its main active metabolite N-desmethyl-imatinib be developed?

(2012) Peggy Gandia et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Determination of unbound fraction of imatinib and N-desmethyl imatinib, validation of an UPLC–MS/MS assay and ultrafiltration method

(2012) Cécile Arellano et al.   JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES

Use of Total and Unbound Imatinib and Metabolite LC-MS/MS Assay to Understand Individual Responses in CML and GIST Patients

(2011) Frank Streit et al.   THERAPEUTIC DRUG MONITORING

Imatinib Plasma Levels Are Correlated With Clinical Benefit in Patients With Unresectable/Metastatic Gastrointestinal Stromal Tumors

(2009) George D. Demetri et al.   JOURNAL OF CLINICAL ONCOLOGY

Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial

(2009) Ronald P DeMatteo et al.   LANCET

Long-Term Results From a Randomized Phase II Trial of Standard- Versus Higher-Dose Imatinib Mesylate for Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing KIT

(2008) Charles D. Blanke et al.   JOURNAL OF CLINICAL ONCOLOGY